Study identifies RGS4 protein as potential target for chronic pain

By targeting this protein

Researchers at Boston University School of Medicine have identified a protein called RGS4 as a possible target for treating chronic pain that persists after nerve injury. The study, published in October 2026, focuses on how damaged peripheral nerves continue to send pain signals long after the initial injury has healed. This ongoing signaling alters how the spinal cord and brain process pain, leading to lasting discomfort. The findings suggest that blocking RGS4 could help interrupt this cycle and reduce chronic pain symptoms. Peripheral nerve damage often results from trauma, surgery, or conditions like diabetes, and when nerves fail to regenerate properly, they become hyperactive. This constant barrage of pain signals triggers changes in the central nervous system, amplifying pain perception over time. The research team found that RGS4 levels increase in injured nerves and contribute to sustained pain signaling.

By targeting this protein, scientists hope to develop therapies that prevent the nervous system from becoming overly sensitive to pain. How RGS4 influences pain signaling in damaged nerves In laboratory models, mice with peripheral nerve injury showed elevated RGS4 expression in sensory neurons. When researchers suppressed RGS4 activity, the animals exhibited reduced pain responses without affecting normal sensation. This indicates that RGS4 plays a specific role in pathological pain rather than general nerve function. The protein appears to regulate G-protein signaling pathways that, when dysregulated, lead to prolonged neuronal excitability. These results suggest RGS4 acts as a molecular switch that maintains the pain state after injury. Can blocking RGS4 prevent long-term pain without side effects? Early experiments suggest that inhibiting RGS4 does not impair motor function or cause noticeable side effects in test subjects.

Unlike some pain treatments that affect cognition or carry addiction risks

Unlike some pain treatments that affect cognition or carry addiction risks, targeting RGS4 may offer a more precise approach. However, researchers caution that human trials are still needed to confirm safety and effectiveness. The next step involves developing compounds that can selectively block RGS4 in peripheral nerves. If successful, this strategy could help patients suffering from neuropathic pain conditions such as post-surgical pain or diabetic neuropathy. Frequently Asked Questions What is RGS4 and why is it linked to chronic pain? RGS4 is a protein that regulates cellular signaling pathways. In injured peripheral nerves, its increased activity helps maintain a state of constant pain signaling, making it a potential target for intervention. How did researchers test the role of RGS4 in pain? They used mouse models of peripheral nerve injury and measured pain responses after suppressing RGS4, observing reduced pain without loss of normal sensation.

Could this lead to new treatments for humans? While promising, the findings are still preclinical. Further research is needed to develop safe inhibitors and test them in human trials before any clinical application.